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esponsibility of Xi’Abstract In the present study, comprehensive stress testing of amlodipine (AM) was carried out
according to International Conference on Harmonization (ICH) Q1A(R2) guideline. AM was subjected to
acidic, neutral and alkaline hydrolysis, oxidation, photolysis and thermal stress conditions. The drug
showed instability in acidic and alkaline conditions, while it remained stable to neutral, oxidative, light
and thermal stress. A total of nine degradation products (DPs) were formed from AM, which could be
separated by the developed gradient LC method on a C18 column. The products formed under various
stress conditions were investigated by LC–MS/MS analysis. The previously developed LC method was
suitably modiﬁed for LC–MS/MS studies by replacing phosphate buffer with ammonium acetate buffer of
the same concentration (pH 5.0). A complete fragmentation pathway of the drug was ﬁrst established to
characterize all the degradation products using LC–MS/MS and multi-stage mass (MSn) fragmentation
studies. The obtained mass values were used to study elemental compositions, and the total information
helped with the identiﬁcation of DPs, along with its degradation pathway.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The stability testing of drugs under different stress conditions is
indispensable during the drug development process. In addition,sity. Production and hosting by Elsev
5
286545; fax: þ91 2563 286552.
om (R.N. Tiwari).
an Jiaotong University.stability testing guidelines stated by International Conference on
Harmonization (ICH) and other international agencies [1,2] require
the reporting, identiﬁcation and characterization of degradation
products (DPs). But DPs generated during storage may be in very
low levels; therefore, stress studies are suggested to generate them
in higher amounts [3]. Still sometimes it is very difﬁcult to identify
these DPs from the generated stressed mixture due to their lower
amounts. As a result, hyphenated techniques like LC–MS areier B.V. All rights reserved.
R.N. Tiwari et al.34currently extensively used for this purpose [4,5]. Amlodipine
(AM) (Fig. 1) is chemically 2-[(2-aminoethoxy) methyl]-4-(2-
chlorophenyl)-1,4-dihydro-6-methyl-3,5 pyridinedicarboxylic acid
3-ethyl 5-methyl ester. It acts as a calcium channel blocker and
inhibits the transmembrane inﬂux of calcium ions into vascular
smooth muscles and cardiac muscle; hence, it used as an
antihypertensive for the treatment of angina.
A thorough literature review revealed that there exist several
reports on bioanalytical method of development and pharmacokinetic
studies of AM [6,7]. A wide array of articles are reported on
stability-indicating HPLC method for the estimation of a single drug
amlodipine in pure bulk samples, dosage forms as well as in
combination with other drugs such as atorvastatin, benazepril,
perindopril, olmesartan, valsartan, and hydrochlorthiazide [8–16].
A few articles are available on photostability studies of AM, where
the thermal degradation kinetics are reported from 0 h to 108 h
[17–20]. There exists report on isolation and characterization of three
thermal degradation products of AM, which were formed due to
intramolecular reactions and cyclization [21]. Moreover, there are
few reports on isolation and characterization of process-related
impurities of AM and accelerated stability studies. From the above
literature, the reported masses and fragmentation pattern of all the
degradation products/impurities of AM are quite different from those
of our degradation products of AM formed under different stress
conditions. In fact, the reported masses of impurities and their
fragment ions were compared with the masses of DPs proposed in
this article and they were all found non-resembling with each other.
Moreover, as per previous reports [22–26] the masses of six different
process-related impurities such as m/z 538, 569, 406, 394, 408 and
422 did not match with the masses of any of the DPs of AM. Hence,
the endeavor of our present study was to: (i) carry out the stress
studies on AM under the ICH-deﬁned conditions; (ii) separate the
degradation products by HPLC; and (iii) characterize and establish
the degradation pathway of all the degradation products with the help
of LC–MS/MS.Fig. 1 Structure of amlodipine.
Table 1 Interpretation of MS data of fragments of amlodipine.
Peak
No.
Experimental
mass
Best possible molecular
formulae
RDB Possible pare
fragment
1 408.90 C20H26N2O5Cl
þ 8.5
2 392.23 C20H23NO5Cl
þ 9.5 1
3 294.13 C15H17NO3Cl
þ 7.5 2
4 238.10 C12H13NO2Cl
þ 6.5 3
5 208.14 C12H18NO2
þ 4.5 4
6 102.13 C5H12NO
þ 0.5 2
RDB: ring plus double bonds.2. Experimental
2.1. Drug and reagents
Pure AM was obtained as gratis sample from Osaka Pharmaceu-
ticals Pvt. Ltd. (Vadodara, India). Analytical reagent (AR) grade
formic acid and sodium hydroxide (NaOH) were purchased from
S.D. Fine-Chem Ltd. (Mumbai, India), hydrochloric acid (HCl)
and HPLC grade methanol (MeOH) from Merck Specialities Pvt.
Ltd. (Mumbai, India), and hydrogen peroxide (H2O2) from
Qualigens Fine Chemicals Pvt. Ltd. (Mumbai, India). Ultra-pure
water obtained from Millipore water puriﬁcation system (Mol-
sheim, France) was used throughout the studies.
2.2. Equipment
A high-performance liquid chromatography (HPLC) system from
PerkinElmer (Shelton, CT, USA) used for the LC studies consisted
of an on-line degasser, a sample injector (Rheodyne sample loop
20 mL), a UV–visible detector (Series 200), a pump (Reciprocat-
ing, series 200), and a computer system loaded with Total Chrome
Navigator (version 6.3.1) software. The LC–MS system was
controlled by Xcalibur software (version 2.0) consisting of LCQ
Fleet and TSQ Quantum Access with Surveyor Plus HPLC System
(Thermo, San Jose, USA). Precision water baths equipped with
MV controller (Thermostatic Classic Scientiﬁc India Ltd. Mumbai,
India) 90 were used for stress studies. Degradation experiments in
acid, base, and neutral conditions were performed using a dry-bath
(Labline Sun Scientiﬁcs Ltd. New Delhi, India). The solid state
thermal stress studies were carried out in a dry-air oven (NSW
Limited, New Delhi, India). Other equipment used was a pH meter
(Labindia, Mumbai, India), a weighing balance (Shimadzu,
AUX220, Kyoto, Japan), and a micro-pipette (Erba Biohit,
Mannheim, Germany). In all studies, separations were achieved
on a C18 column (250 mm 4.6 mm i.d., particle size 5 mm;
Kromasil (Eka Chemicals AB, Bohus, Sweden)). Photolytic
studies were carried out in a photostability chamber (Thermolab,
95 Th-400G Mumbai, India), set at 4071 1C/7573% RH in
accordance with option two of the ICH guideline Q1B [27].
2.3. Stress degradation studies
Stress degradation studies were carried out on AM as per ICH
Q1A(R2)-prescribed stress conditions. As per ICH the stress
degradation studies are conducted to determine the stability of
drug substances or drug products by knowing the degradationnt Difference from
parent ion
Possible losses corresponding to
difference
16.67 NH3
98.10 C5H6O2
56.03 C3H4O
29.96 HCl
290.10 C15H11O4Cl
Table 2 LC–MS/MS data of DPs of amlodipine (AM) along with their possible molecular formulae and major fragments.
DPs Experimental
mass
Best possible
molecular formula
RDB Major fragments (chemical formula)
AM1 363.08 C19H27N2O5
þ 8.5 292.92 (C16H22NO4þ), 226.83 (C14H12NO2þ), 157.00 (C8H15NO2þ), 112.92 (C6H8O2þ)
AM2 392.67 C20H23NO5Cl
þ 9.5 347.08 (C18H18NO4Cl
þ), 305.92 (C16H16NO3Cl
þ), 158.92 (C8H16NO2þ), 113.08
(C6H11NO
þ)
AM4 399.92 C19H28N2O5Cl
þ 7.5 363.83 (C19H27N2O5þ), 331.92 (C17H16N2O3Cl
þ), 263.08 (C14H16N2OCl
þ), 158.58
(C8H16NO2þ), 106.92 (C7H6O
þ), 90.75 (C4H12NO
þ)
AM5 380.83 C19H23NO5Cl
þ 9.5 302.25 (C17H20NO4þ), 284.83 (C16H14NO4þ), 222.00 (C13H20NO2þ), 192.00
(C11H14NO2þ), 175.08 (C11H11O2þ), 142.92 (C7H12NO2þ)
AM6 393.00 C19H22N2O5Cl
þ 9.5 306.42 (C16H17NO3Cl
þ), 218.17 (C13H16NO2þ), 158.75 (C11H12N
þ), 112.75 (C6H10NO
þ),
90.92 (C4H12NO
þ)
AM7 380.75 C18H21N2O5Cl
þ 9.5 352.83 ( C18H13NO4Cl
þ), 335.92 (C17H18NO4Cl
þ), 230.83 (C14H16NO2þ), 163.17
(C9H9NO2þ)
AM8 407.17 C20H24N2O5Cl
þ 10.5 286.08 (C17H20NO3þ), 231.25 (C15H21NO
þ), 123.92 (C8H11O
þ)
AM9 395.00 C19H24N2O5Cl
þ 9.5 366.75 (C18H21NO5Cl
þ), 350.08 (C17H17NO5Cl
þ), 302.17 (C16H13NO3Cl
þ), 244.17
(C14H14NO3þ), 226.25 (C14H12NO2þ), 102.25 (C4H8NO2
þ)
RDB: ring plus double bonds.
Fig. 2 Chromatogram showing separation of degradation products of
amlodipine (AM) in the mixture of stress sample. A: acid; B: base;
N: neutral; RT: retention time.
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the guideline explicitly requires the conduct of forced degradation
studies under a variety of conditions like a wide range of pH, light,
oxidation and dry heat. AM along with various stressors was
exposed to different temperatures with the objective to achieve
15–20% degradation and for this the stress conditions were
systematically optimized in the initial stages. AM was subjected
to acidic (1 M HCl, 30 min, 80 1C), basic (1 M NaOH, 1 h, 80 1C),
neutral (H2O, 2 h, 80 1C), oxidative (H2O2, 15%, 48 h) at room
temperature, thermal (50 1C, 48 h) and photolytic (1.2 106 lx h
of ﬂuorescent light and 200 Wh/m2 UV-A light, 14 days) stress
conditions.
2.4. Sample preparation for HPLC and LC–MS analysis
The stressed samples of AM collected during the desired time
intervals were adequately diluted 10 times with water before
injection into the HPLC. Moreover, the samples were ﬁltered
through a 0.22 mm membrane ﬁlter before making injections.
A mixture containing all the degradation products was also
prepared for ﬁnal HPLC separation and LC–MS analysis. In total
100 mg/mL samples were prepared and injected so as to adequatelycompare the percentage degradation with the standard unstressed
drug sample of the same concentration.2.5. Separation studies
A concentration of 10 mg/mL of AM was scanned from 200 to
400 nm in the ultraviolet spectrophotometer to select UV
wavelength suitable for HPLC analysis. From the spectra,
240 nm wavelength was found to show maximum absorbance.
First separation of AM was attempted by varying the relative
ratio of methanol to phosphate buffer, along with the variation
in buffer pH. All the separations were carried out using a C18
column. Separation studies were ﬁrst carried out on all reaction
solutions individually, and then on a mixture of degraded drug
solutions.2.6. MS, MSn and LC–MS studies
The fragmentation proﬁle of the drug was established by carrying
out mass spectral studies on AM, while multi-stage (MSn) mass
studies were carried out up to MS6 to determine the origin of each
fragment. AM was subjected to MS system at a concentration of
10 mg/mL prepared in methanol in positive electrospray ionization
(ESI) mode in the mass range of 50–800 Da. High-purity nitrogen
was used as the nebulizer and auxiliary gas. The interpretation data
of fragments obtained in MS studies for AM are listed in Table 1.
A previously developed LC method was used to analyze degraded
drug samples on the LC–MS system, and provided phosphate
buffer was replaced by 10 mM ammonium acetate buffer of pH
5.0. The mass parameters were properly tuned to obtain high-
intensity peaks of molecular ions and daughter ions of degradation
products. The fragments of all DPs obtained in LC–MS studies
along with the best possible molecular formula, ring plus double
bonds (RDB) and chemical formula of major fragments are shown
in Table 2.
Fig. 3 Line spectra of amlodipine obtained in MS and MSn
studies.
Fig. 4 Mass fragmentation pattern of amlodipine.
R.N. Tiwari et al.363. Results and discussion
3.1. HPLC analysis
During the initial separation trials, methanol and water were
adopted as a mobile phase on different gradient LC modes, but
the separation of drugs and degraded products was not optimum;
this might be due to the poor buffering capacity of water. Then in
the later trials water was replaced with phosphate buffer. Stronger
organic modiﬁer viz., acetonitrile, was not utilized during the
HPLC analysis, since methanol showed satisfactory resolution
between drugs and degraded products, and hence it was kept
unchanged. Logical modiﬁcations like change in pH and gradient
program were made to improve the resolution between drug and
degradation products and also between the degradation products.
Finally an acceptable separation was achieved using methanol and
phosphate buffer (10 mM, pH 5.0) in a gradient mode (Tmin/A:B;
T0/10:90; T8/50:50; T13/60:40; T25/75:25; T27/10:90;T30/10:90)
on C18 column at room temperature. The detection wavelength
was 240 nm, ﬂow rate was 1 mL/min, and injection volume was
20 mL.3.2. Stress decomposition behavior
A total of nine DPs AM1–AM9 were formed from AM during the
stress degradation study. Out of these AM2, AM3, AM5, AM6 and
AM7 were formed as major DPs, while AM1, AM4, AM8 and
AM9 were minor DPs. Among all the DPs AM1, AM6 and AM9
were formed in both acidic and alkaline conditions, while the
products AM2, AM3, AM4 and AM5 were formed only under
alkaline stress condition, and AM7 was the product of acidic stress.
A total of 16.41% degradation was observed in acid stress, while in
Fig. 5 Line spectra of degradation products of amlodipine obtained in LC–MS/MS studies.
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Fig. 6 Degradation products of amlodipine formed under acidic and alkaline stress conditions (AM1, AM2, AM4 and AM5).
R.N. Tiwari et al.38alkaline stress 27.53% degradation was recorded. The chromato-
gram showing separation of AM and all the DPs is shown in Fig. 2.
The degradation products of AM are denoted as AM1 to AM9 in
accordance with the sequence in which the peak appeared from left
to right in the chromatogram. From the chromatogram AM was
found to be more susceptible to alkaline stress.3.3. Mass fragmentation pattern of AM
A total of six fragments were formed from AM during its MS
studies. A multi-stage (MSn) mass fragmentation study was also
carried out up to MS6, to determine the origin of each fragment,
which could help propose the fragmentation pathway of AM. Line
spectra of AM, obtained in MS and MSn studies, are shown in
Fig. 3. The fragment with m/z 431.23 was formed as a potassium
adduct, since its mass was 28 Da higher than the molecular ion
peak of AM (m/z 408.90). The fragments with m/z 392.23 were
formed on loss of ammonia (NH3) from AM, while in the
subsequent step the fragment with m/z 392.23 on cleavage of
methyl but-2-enoate moiety resulted in the formation of m/z 294.13.
There onwards a parallel pathway was initiated from the fragment
with m/z 294.13; here a direct loss of methoxy ethane entity led to
the formation of a daughter ion with m/z 238.10, while loss of 1-
chloro-2-methyl benzene and propionic acid moieties resulted in theformation of the last daughter ion with m/z 102.13. Finally the
fragment with m/z 238.10 underwent cleavage of hydrogen chloride
entity and resulted in the formation of ion with m/z 208.14. The
mass fragmentation pattern of AM is shown in Fig. 4.3.4. Characterization of degradation products
The data obtained in MS, MSn and LC–MS/MS studies were
systematically utilized for the structure elucidation of degradation
products of AM.3.4.1. AM1 (m/z 363.08)
As shown in Fig. 2, AM1 was formed as the ﬁrst degradation product
and the most polar DP among all because of its immediate elution
after the solvent front at 2.87 min of retention time. LC–MS/MS line
spectra of AM1 in Fig. 5 show the formation of fragments with m/z
363.08, m/z 292.92, m/z 226.83, m/z 157.00 and m/z 112.92, and
among these the m/z 363.08 and m/z 157.00 were formed as
molecular ion and base ion peaks, respectively, since 472.75 cannot
be considered as the molecular ion peak of AM1 because of its huge
difference in the molecular mass compared to the molecular mass of
AM (m/z 409). Hence, AM1 was obtained from the drug by the loss
of hydrogen chloride entity of benzene ring and a methyl group from
Fig. 7 Degradation products of amlodipine formed under acidic and alkaline stress conditions (AM6, AM7 AM8 and AM9).
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The fragmentation pattern of AM1 is shown in Fig. 6.3.4.2. AM2 (m/z 392.67)
A total of ﬁve line fragments were formed from AM2, viz., m/z
392.67, m/z 347.08, m/z 305.92, m/z 158.92 and m/z 113.08.
Among these the fragment with m/z 392.67 was the molecular ion
peak, while the one with m/z 347.08 was the base peak. AM2 was
formed on loss of ammonia (NH3) from terminal position of the
side chain attached at the second position of 1,4-dihydropyridine
ring. The subsequent steps in the fragmentation pathway of AM2
are shown in Fig. 6, which involved conversion of ester to
aldehyde (m/z 347.08) intermediate, followed by the formation
of fragments with m/z 305.08, m/z 158.11 and m/z 113.08, due to
losses such as ethanol, methyl formate, chlorobenzene and
methoxymethane entities. The impurity with m/z 392.2 reported
by Reddy et al. [22] was formed during accelerated stability
studies. Although this impurity had the same mass as that of AM2
but showed different MS/MS fragmentation pattern, the proposed
structure of AM2 was different. The major ions formed during
MS/MS of this impurity (m/z 392.2) were m/z 360.2, 346.5, 318.1
and 286.2, while the fragment ions formed from AM2 were m/z
347.08, 305.92, 158.92 and 113.08. The fragmentation pattern of
AM2 is shown in Fig. 6.3.4.3. AM3
The structure of AM3 degradation product was not elucidated,
probably due to its poor ionization behavior during LC–MS/MS
analysis in both ESI positive and ESI negative ionization modes.
3.4.4. AM4 (m/z 399.92)
As shown in Fig. 5, AM4 had the molecular ion peak of 399.92,
with the base peak of 331.92. The drug (AM) underwent loss of
a methyl group from ethyl 1,4-dihydropyridine-3-carboxylate
and resulted in the formation of AM4. There onwards AM4
followed a parallel fragmentation pathway involving loss of
hydrogen chloride and acetate moiety to form ions with m/z
363.83 and m/z 331.92, respectively. A loss of another acetate
moiety and a methyl group from m/z 331.92 resulted in the
formation of fragment with m/z 263.08. The formation of other
minor fragments along with their structures and masses is
depicted in Fig. 6.
3.4.5. AM5 (m/z 380.83)
A total of seven fragments were formed from AM5, where a
fragment with m/z 380.83 was formed as the base peak as well as
molecular ion peak. A direct cleavage of terminal methamine
entity of the side chain attached to the second position of 1,4-
dihydropyridine ring resulted in the formation of AM5. Ion with
Fig. 8 Degradation pathway of amlodipine.
R.N. Tiwari et al.40m/z 302.25 was formed from AM5 on loss of hydrogen chloride
and dimethyl ether entities. Ion with m/z 302.25 underwent loss of
two ring protons and a methyl group attached to the sixth position
of 1,4-dihydropyridine ring and led to the formation of fragment
with m/z 284.09. Subsequent losses such as acetate and methylene
entity resulted in dihydropyridine ring opening to form an ion with
m/z 222.00. The structures and masses of daughter ions with m/z
192.00, m/z 175.08 and m/z 142.92 formed in the same pathway
are shown in Fig. 6.3.4.6. AM6 (m/z 393.00)
The mass of AM6 was found to be m/z 393.00, which suggests
loss of a methyl group from AM along with the charge migration
from terminal amine to the sixth carbon of 1,4-dihydropyridine
ring. AM6 in its subsequent steps lost the ethyl carboxylate entity
to form a daughter ion with m/z 306.42, which on ring opening and
cleavage of a larger fragment of around 216 Da resulted in the
formation of ion with m/z 90.92. On the other hand, fragment with
m/z 306.42 on loss of methoxyethane and hydrogen chloride led to
the formation of fragment ion with m/z 218.17, which followed a
minor parallel pathway with the formation of daughter ions with
m/z 158.75 and m/z 112.75 on loss of methylcarboxylate and
benzene moieties, respectively. The proposed structures of all the
fragments of AM6 are shown in Fig. 7.3.4.7. AM7 (m/z 380.75)
The ester functional group at the third position of 1,4-dihydropyr-
idine underwent hydrolysis with the loss of ethyl group and
resulted in the formation of AM7 with m/z 380.75 The loss of 2-
aminoethanol from the second position of 1,4-dihydropyridine
along with two ring protons resulted in the formation of fragment
with m/z 352.83, which on loss of a methyl group led to the
formation of a fragment with m/z 335.92. Then m/z 335.92
followed a parallel fragmentation to form an ion with m/z
230.83 on loss of hydrogen chloride and ethylcarboxylate entities,
while ion of m/z 163.17 was formed on loss of chlorobenzene,
methylcarboxylate and two ring protons. The proposed structures
of all the fragments of AM7 are shown in Fig. 7.
3.4.8. AM8 (m/z 407.17)
As shown in Fig. 5, AM8 had the mass of m/z 407.17, which
indicates around mass of 2 Da lesser (around two protons) than the
mass of drug (AM). AM8 would be the result of one of the main
degradation pathways of AM such as oxidative aromatization of
dihydropyridine fragment to the pyridine moiety, which takes
place in solution and solid states as well as under photolytic
conditions [28]. One of the degradation products reported by
Damale et al. [29] had the same mass of m/z 407 formed under
oxidative and acidic stress conditions. The ﬁrst fragment of AM8
had the mass of m/z 286.08 formed on losses of ammonia,
Characterization of degradation products of amlodipine by LC–MS/MS 41ethylcarboxylate and hydrogen chloride. Then the fragment with
m/z 286.08 on loss of methylcarboxylate resulted in the formation
of ion with m/z 231.25, which in its subsequent step lost ring
nitrogen, methyl group and a benzene entity to form daughter ion
with m/z 123.92. The proposed structures of all the fragments of
AM8 are shown in Fig. 7.
3.4.9. AM9 (m/z 395.00)
A direct cleavage of methyl group from the sixth position of 1,4-
dihydropyridine ring of the drug (AM) resulted in the formation of
AM9 with m/z 395.00. There onwards AM9 followed a parallel
fragmentation pathway. In its subsequent steps loss of methana-
mine and o-demethylation of the side chain resulted in the
formation of fragments with m/z 366.75 and m/z 350.08, respec-
tively. On the other hand, AM9 on loss of ethylcarboxylate and
ammonia from the side chain resulted in the formation of ion with
m/z 302.17. The same degradation product with m/z 395 reported
by Damale et al. [29] was formed under alkaline stress, while in
our case this DP was formed in acidic and alkaline conditions. The
proposed structures of all the fragments of AM9 are shown in
Fig. 7.
3.5. Degradation pathway of AM
Based on the data obtained from the line spectra of LC–MS/MS
studies of each degradation product, a ﬁnal fragmentation pathway
of AM was established. The degradation pathway of AM is shown
in Fig. 8 along with the proposed structures and masses of all
the DPs.4. Conclusion
Stress degradation studies were carried out on AM as per
mentioned ICH guidelines, which provided information on the
degradation behavior of AM under the acidic, basic, neutral,
oxidative, photolytic and thermal stress conditions. HPLC analysis
revealed that a total of nine degradation products were formed
from AM, among these AM3 remained unidentiﬁed probably due
to its poor ionization behavior, while all the remaining DPs were
successfully characterized with the help of LC–MS/MS analysis.
The above-stated study was able to explore various useful
information which is not yet reported in the literature on AM
such as (a) sensitivity of AM to different stress conditions, (b) the
total number of degradation products of AM along with the nature
of DPs, (c) mass fragmentation pathway of AM as well as its DPs,
(d) MSn study of the drug to determine the origin of each mass
fragment, and (e) degradation pathway of the drug.
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